Artificial intelligence in breast cancer imaging: a systematic review of detection, segmentation, explainability, and clinical translation

Vollständiger Abstract

Worum geht es in dieser Arbeit?

Introduction Breast cancer remains the most commonly diagnosed malignancy in women worldwide, with approximately 2.3 million new cases and 670,000 deaths in 2022. Artificial intelligence (AI) is increasingly being applied across breast imaging for detection, characterization, segmentation, risk stratification, explainability, and clinical translation. Methods This systematic review synthesized 284 eligible peer-reviewed publications published between 2015 and 2025, identified through a PRISMA 2020-compliant search of four indexed databases. A supplementary relevance-ranked Google Scholar screen was reported separately. A targeted May 2026 narrative update of recent prospective and implementation studies was also conducted without adding these records to the PRISMA denominator. Results The reviewed evidence encompassed classical machine learning and radiomics, convolutional neural networks, YOLO-family detectors, vision transformers and hybrid CNN-Transformer architectures, U-Net variants, Mask R-CNN, SAM, and MedSAM across mammography, tomosynthesis, MRI, ultrasound, contrast-enhanced mammography, and emerging photoacoustic imaging. The evidence highlights advances in explainable AI, multimodal and radiogenomic fusion, federated learning, and open-source deployment, while persistent challenges include data heterogeneity, class imbalance, domain shift, bias, incomplete calibration, and limited prospective validation. Retrospective benchmark findings were derived from the 284-study systematic corpus, whereas prospective clinical utility and real-world implementation were informed by the separate 2026 narrative update. Discussion AI shows substantial potential to enhance breast cancer imaging, but broader clinical translation requires robust external and prospective validation, improved calibration, assessment of generalizability and bias, and integration into clinical workflows. Supplementary Data Sheet S1 should be interpreted as a provenance-tagged evidence map rather than a formal study-level risk-of-bias assessment, with 38 entries verified from full text, 48 based on abstracts, and 198 based on DOI/source pages or other web-accessible records.